During the past decade, Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 11 clinical trials were completed, i.e. on average, 84.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 9 clinical trials were completed. i.e. 180% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos" #1 sponsor was "Celgene" with 6 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Janssen-Cilag Ltd." with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos" are "Eosinophilic Esophagitis" (2 trials), "HIV-1" (2 trials), "Leukemia, Myeloid, Acute" (2 trials), "Urothelial Cancer" (2 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos" in a lesser frequency.

Most popular intervention types in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos" are "Drug" (19 trials), "Other" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Avelumab" (2 trials), "CC-93538" (2 trials), "Carboplatin" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos". undefined are not yet recruiting, 5 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".